All In Biotech

Drug Trial Radar · NCT06060613

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

254

Planned (sponsor's estimate)

Start

Oct 25, 2023

Primary completion

Jun 30, 2029

Study completion Jun 30, 2029

Sponsor

Lead sponsor
Obsidian Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

Conditions

  • Tumor Skin
  • Metastatic Melanoma
  • Melanoma
  • Lung Cancer
  • Metastatic Lung Cancer
  • Non Small Cell Lung Cancer
  • Metastatic Non Small Cell Lung Cancer

Interventions

  • OBX-115Biological

    A tumor sample is obtained from each participant for autologous OBX-115 manufacture. After lymphodepletion including cyclophosphamide and fludarabine, participant will receive OBX-115 infusion, followed by short courses of acetazolamide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and nature of dose-limiting toxicities (DLTs)Time frame: 28 Days
  2. The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1Time frame: 2 years
  3. The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1Time frame: 2 years

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • Banner Health

    Tucson, Arizona · Recruiting

  • The Angeles Clinic and Research Institute (Melanoma)

    Los Angeles, California · Recruiting

  • USC Norris Comprehensive Cancer Center (Melanoma/NSCLC)

    Los Angeles, California · Recruiting

  • Stanford Cancer Institute (Melanoma/NSCLC)

    Stanford, California · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Advent Health Orlando

    Orlando, Florida · Recruiting

  • Orlando Health Cancer Institute (Melanoma/NSCLC)

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • James Graham Brown Cancer Center (Melanoma/NSCLC)

    Louisville, Kentucky · Recruiting

  • Memorial Sloan Kettering (Melanoma/NSCLC)

    New York, New York · Recruiting

  • The Ohio State University

    Columbus, Ohio · Active not recruiting

  • Allegheny Research Institute (Melanoma/NSCLC)

    Pittsburgh, Pennsylvania · Recruiting

  • M.D. Anderson Cancer Center (Melanoma/NSCLC)

    Houston, Texas · Recruiting

  • Melanoma Institute of Australia

    Wollstonecraft, New South Wales, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.